Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 Vancouver chiropractic clinic, ... two awards in the prestigious Vancouver Courier “Stars ... 27, 2015. The company secured third place in ... the “Best Registered Massage Therapist” category. , ... in Canada, The Vancouver Courier is a semiweekly ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 As ... Endometriosis can be a painful condition in ... spreading outside of the uterus leading to very unpleasant ... families. Endometriosis can have a terrible effect on women’s ... is also the most common cause of infertility in ...
(Date:3/4/2015)... The report covers spices market upstream ... industry development trend and proposals. The report provides ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:3/4/2015)... 2015 Plungerhead has partnered ... members during and after their service to the country. ... awareness through advertising, social media and several national special ... organization through a special retail promotion of Plungerhead Lodi ... through May 2015. , “There is a vital ...
(Date:3/4/2015)... New York, NY (PRWEB) March 04, 2015 ... hit talk show “The Real” graces the cover of the ... by encouraging readers to choose organic when shopping for clothes ... medalist Nastia Liukin opens up about her commitment to an ... given me more energy, not only in gymnastics, but also ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 3
... Neuisys Imaging System,Solutions, LLC announced today that the U.S. ... the NeuViz 16 Multi-Slice Computed,Tomography (CT) System. The NeuViz ... venture between Royal Philips Electronics of the Netherlands,and Neusoft ... NeuViz 16 is a state-of-the-art CT system that provides ...
... hypertension during pregnancy, Marshal D. Lindheimer, MD, professor emeritus ... Medicine and in the Committee on Clinical Pharmacology and ... 2009 Joseph Bolivar DeLee Humanitarian Award from the Board ... University of Chicago Medical Center. , The ...
... Accounting Related to Two Transactions , PHOENIX, Feb. 23 ... in stabilized rice bran (SRB) nutrient research and technology, ... recommendations of the Audit Committee of its Board of ... fiscal year ended December 31, 2007. This includes the ...
... 23 HealthyPlace.com , which provides the most extensive ... the internet, unveils several important new features for those ... features HealthyPlace Mediminder , a free medication reminder ... them to take their medication or refill their prescription. ...
... Fiber Bring Great Taste and Digestive Health Benefits to ... Company, Inc., announced today that it will expand the ... probiotic portfolio. Both cultured fresh dairy products, Activia Dairy ... the same scientifically proven benefits of all Activia products, ...
... say yes, but American experts aren,t so sure , , ... Taiwan links aggression in teens to heavy Internet use, ... , The research, based on questionnaires about Internet ... percent of the boys and 13 percent of the girls ...
Cached Medicine News:Health News:Neuisys Announces FDA Clearance of NeuViz 16 Multi-Slice CT System 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 2Health News:NutraCea to Restate Financial Statements for 2007 and 2008 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 5Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 2Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 3Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 2Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 3Health News:Are Internet-Addicted Kids More Violent? 2
(Date:3/4/2015)... 4 mars 2015  RedHill ... ou la « Société »), une société ... les spécialités pharmaceutiques administrés par ... clinique avancé pour les maladies ... les cancers gastro-intestinaux, a annoncé ...
(Date:3/4/2015)... Company plc (NYSE: PRGO ; TASE) today announced ... will present at the 2015 Barclays Global Healthcare Conference ... Loews Miami Beach Hotel in Miami, FL. ... http://perrigo.investorroom.com/events-webcasts . From its beginnings as a packager ... in Ireland , has grown to become ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 2RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 3RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 5Perrigo Company To Present At The 2015 Barclays Global Healthcare Conference 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... resistance ... in small cell lung cancer -, SOUTH SAN FRANCISCO, Calif., ... company focused,on oncology, today announced that preliminary data from a Phase ... tumors will be,presented at the 2008 American Association for Cancer Research ...
... BRUSSELS and NEWARK, New Jersey, March 19 ... the UMDNJ-University Hospital,(UH) in Newark, New Jersey from ... interventions to improve outpatient care and,access for people ... teaching hospital provides care for a low-income, minority,population ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting 3UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation 2UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation 3UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: